ENVERIC BIOSCIENCES, INC. Research and Development Expense
ENVERIC BIOSCIENCES, INC. (ENVB) reported Research and Development Expense of $1.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- ENVERIC BIOSCIENCES, INC. research and development expense for the quarter ending 2026-06-30 was $1.36M, a 7.55% increase year-over-year.
- ENVERIC BIOSCIENCES, INC. research and development expense for the quarter ending 2026-03-31 was $345.97K, a 53.65% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. research and development expense for the quarter ending 2025-12-31 was $372.18K, a 61.53% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. research and development expense for the quarter ending 2025-09-30 was $402.42K, a 49.87% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. research and development expense for fiscal 2025 was $2.78M, a 2.12% decline from fiscal 2024.
- ENVERIC BIOSCIENCES, INC. research and development expense for fiscal 2024 was $2.84M, a 60.82% decline from fiscal 2023.
- ENVERIC BIOSCIENCES, INC. research and development expense for fiscal 2023 was $7.25M, a 9.66% decline from fiscal 2022.
- ENVERIC BIOSCIENCES, INC. research and development expense for fiscal 2022 was $8.03M, a 67.64% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.36M 10-Q · filed 2026-08-14 | $1.70M 10-Q · filed 2026-08-14 | $2.07M derived: sum of 3 quarters · filed 2026-08-14 | $2.48M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | $345.97K 10-Q · filed 2026-05-15 | $718.15K derived: sum of 2 quarters · filed 2026-05-15 | $1.12M derived: sum of 3 quarters · filed 2026-05-15 | $2.38M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | $372.18K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $774.60K derived: sum of 2 quarters · filed 2026-03-27 | $2.03M derived: sum of 3 quarters · filed 2026-08-14 | $2.78M 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $402.42K 10-Q · filed 2025-11-14 | $1.66M derived: sum of 2 quarters · filed 2026-08-14 | $2.41M 10-Q · filed 2025-11-14 | $3.38M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | $1.26M 10-Q · filed 2026-08-14 | $2.01M 10-Q · filed 2026-08-14 | $2.97M derived: sum of 3 quarters · filed 2026-08-14 | $3.78M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $746.37K 10-Q · filed 2026-05-15 | $1.71M derived: sum of 2 quarters · filed 2026-05-15 | $2.52M derived: sum of 3 quarters · filed 2026-05-15 | $3.08M derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2024-12-31 | $967.40K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.77M derived: sum of 2 quarters · filed 2026-03-27 | $2.34M derived: sum of 3 quarters · filed 2026-03-27 | $2.84M 10-K · filed 2026-03-27 | |||
| 2024-09-30 | $802.72K 10-Q · filed 2025-11-14 | $762.72K 10-Q · filed 2024-11-14 | $1.37M derived: sum of 2 quarters · filed 2025-11-14 | $1.87M 10-Q · filed 2025-11-14 | $1.74M 10-Q · filed 2024-11-14 | $3.59M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $565.00K 10-Q · filed 2025-08-14 | $515.50K 10-Q · filed 2024-08-12 | $1.07M 10-Q · filed 2025-08-14 | $973.66K 10-Q · filed 2024-08-12 | $2.79M derived: sum of 3 quarters · filed 2025-08-14 | $4.07M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $506.15K 10-Q · filed 2025-05-14 | $458.15K 10-Q · filed 2024-05-15 | $2.23M derived: sum of 2 quarters · filed 2025-05-14 | $3.51M derived: sum of 3 quarters · filed 2025-05-14 | $5.90M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $3.00M derived: sum of 2 quarters · filed 2025-03-28 | $5.40M derived: sum of 3 quarters · filed 2025-03-28 | $7.25M 10-K · filed 2025-03-28 | |||
| 2023-09-30 | $1.28M 10-Q · filed 2024-11-14 | $1.35M 10-Q · filed 2023-11-13 | $3.68M derived: sum of 2 quarters · filed 2024-11-14 | $5.53M 10-Q · filed 2024-11-14 | $5.88M 10-Q · filed 2023-11-13 | $7.40M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $2.40M 10-Q · filed 2024-08-12 | $2.51M 10-Q · filed 2023-08-11 | $4.25M 10-Q · filed 2024-08-12 | $4.53M 10-Q · filed 2023-08-11 | $6.11M derived: sum of 3 quarters · filed 2024-08-12 | $8.17M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $1.83M 10-Q · filed 2024-05-15 | $1.99M 10-Q · filed 2023-05-15 | $3.72M derived: sum of 2 quarters · filed 2024-05-15 | $5.77M derived: sum of 3 quarters · filed 2024-05-15 | $7.89M derived: sum of 4 quarters · filed 2024-05-15 | ||
| 2022-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $3.95M derived: sum of 2 quarters · filed 2024-03-26 | $6.07M derived: sum of 3 quarters · filed 2024-03-26 | $8.03M 10-K · filed 2024-03-26 | |||
| 2022-09-30 | $2.06M 10-Q · filed 2023-11-13 | $4.18M derived: sum of 2 quarters · filed 2023-11-13 | $6.13M 10-Q · filed 2023-11-13 | $8.63M derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $2.12M 10-Q · filed 2023-08-11 | $4.08M 10-Q · filed 2023-08-11 | $6.57M derived: sum of 3 quarters · filed 2023-08-11 | $7.79M derived: sum of 4 quarters · filed 2023-08-11 | |||
| 2022-03-31 | $1.96M 10-Q · filed 2023-05-15 | $4.45M derived: sum of 2 quarters · filed 2023-06-09 | $5.67M derived: sum of 3 quarters · filed 2023-06-09 | $6.55M derived: sum of 4 quarters · filed 2023-06-09 | |||
| 2021-12-31 | $2.49M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-09 | $3.71M derived: sum of 2 quarters · filed 2023-06-09 | $4.59M derived: sum of 3 quarters · filed 2023-06-09 | $4.79M 10-K/A · filed 2023-06-09 | |||
| 2021-09-30 | $1.22M 10-Q · filed 2022-11-14 | $2.10M derived: sum of 2 quarters · filed 2022-11-14 | $2.30M 10-Q · filed 2022-11-14 | $2.30M derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $879.84K 10-Q · filed 2022-08-12 | $1.08M 10-Q · filed 2022-08-12 | $1.08M derived: sum of 3 quarters · filed 2022-08-12 | $1.14M derived: sum of 4 quarters · filed 2022-08-12 | |||
| 2021-03-31 | $157.95K 10-Q · filed 2022-05-13 | $197.78K derived: sum of 2 quarters · filed 2022-05-13 | $261.08K derived: sum of 3 quarters · filed 2022-05-13 | $312.04K derived: sum of 4 quarters · filed 2022-05-13 | |||
| 2020-12-31 | $39.82K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $103.13K derived: sum of 2 quarters · filed 2022-03-31 | $154.08K derived: sum of 3 quarters · filed 2022-03-31 | $174.08K 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $63.30K 10-Q · filed 2021-11-15 | $114.26K derived: sum of 2 quarters · filed 2021-11-15 | $134.26K 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | $50.96K 10-Q · filed 2021-08-13 | $70.96K 10-Q · filed 2021-08-13 | |||||
| 2016-12-31 | $55.10K 10-K/A · filed 2017-04-04 | ||||||
| 2011-06-30 | $0.00 10-Q · filed 2011-08-02 | $0.00 10-Q · filed 2011-08-02 | |||||
| 2010-06-30 | $0.00 10-Q · filed 2011-08-02 | $0.00 10-Q · filed 2011-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |